The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 21, Yifang Biotechnology (Shanghai) Co., Ltd. (abbreviation: Yifang Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, and CITIC Securities is its sole sponsor. The company submitted a listing application to the Hong Kong Stock Exchange on January 1 of this year. According to the prospectus, Yifang Biotech was founded in 2013 and is a biopharmaceutical company focusing on tumors, autoimmune diseases and metabolic diseases. Yifang Biotech has eight candidate products, including two self-developed core products, D-2570 and Terisstrone (D-0502). D-2570 is used to treat autoimmune diseases (including psoriasis, ulcerative colitis (“UC”), systemic lupus erythematosus (“SLE”), psoriatic arthritis (“pSA”), and vitiligo), while terisetran (D-0502) is used to treat ER+HER2-breast cancer. Both core products are currently in phase III clinical trials.

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 21, Yifang Biotechnology (Shanghai) Co., Ltd. (abbreviation: Yifang Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, and CITIC Securities is its sole sponsor. The company submitted a listing application to the Hong Kong Stock Exchange on January 1 of this year. According to the prospectus, Yifang Biotech was founded in 2013 and is a biopharmaceutical company focusing on tumors, autoimmune diseases and metabolic diseases. Yifang Biotech has eight candidate products, including two self-developed core products, D-2570 and Terisstrone (D-0502). D-2570 is used to treat autoimmune diseases (including psoriasis, ulcerative colitis (“UC”), systemic lupus erythematosus (“SLE”), psoriatic arthritis (“pSA”), and vitiligo), while terisetran (D-0502) is used to treat ER+HER2-breast cancer. Both core products are currently in phase III clinical trials.